Atrasentan, evaluated as an adjunct to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in the ALIGN trial, showed a 38.1% proteinuria reduction at week 36 compared to 3.1% with placebo (P < 0.001), with no excess risk of heart failure or severe edema.35 This evidence concerns the gene ACE and heart failure.